CEO of Nottingham-based life sciences firm steps down

Employment & Skills | Healthcare | Midlands

Oncimmune, a developer, manufacturer and marketing specialist of personalised immunodiagnostics for the screening, detection and care of cancer, has appointed Dr Adam Hill as chief executive officer.

His appointment follows founder Geoffrey Hamilton-Fairley’s decision to step down as CEO and into a new role as vice chairman of the company’s board of directors, effective 1 October 2018.

Dr Hill joined Oncimmune as chief medical officer, chief scientific officer and executive director earlier this year from McLaren Applied Technologies.

During this previous role, he was chief strategy officer and responsible for its portfolio of health programmes, co-developed in partnership with blue chip pharma and medical device companies.

Commenting on his new role, Dr Hill commented: “Oncimmune has a strong and proprietary position in immune profiling of cancer, and a compelling pipeline of clinical and commercial phase assets that will help unlock the potential of personalised immunodiagnostics for a broad portfolio of cancer indications. 

“As the field of oncology sits on the cusp of dramatically improved cancer survivorship, I look forward to working with the company’s experienced board, and its highly talented executive and scientific teams to take Oncimmune’s immunodiagnostic solutions through clinical development and into the hands of clinicians to improve patient outcomes.”

Outgoing CEO, Geoffrey Hamilton-Fairley added: “It has been a great experience leading Oncimmune from its spin out from Nottingham University and a team of dedicated colleagues and research collaborators who have been working together to transform the treatment of cancer through immunodiagnostics leading to early detection and improved care and outcomes. 

“The company is well positioned for an exciting future and it is now time to transition to new leadership who will take our products and technology through clinical development and broad global commercialisation, and Adam has demonstrated that he is the ideal leader to deliver the next phase of Oncimmune’s growth. 

“My thanks and appreciation to the extended Oncimmune team and partners, past and present.”

Did you enjoy reading this content?  To get more great content like this subscribe to our magazine

Reader's Comments

Comments related to the current article

Leave a comment

Your email address will not be published. Required fields are marked *